Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Heavy chains of human factors Xa and X.|
|Purification||Ion-exchange chromatography, Ammonium sulfate precipitation|
|Storage buffer||50% water with 50% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Inhibition Assays (IA)||5-10 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-43013 detects Factor X in human samples.
MA1-43013 has successfully been used in IA applications.
MA1-43013 was derived from the heavy chains of human factors Xa and X.
F10 undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Coagulation factor 10; F10; factor Xa; prothrombinase; Stuart-Prower factor
F10; FX; FXA